All In Biotech

Investigational drug · Phase 3

EA-230

Also called: hour

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG).

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3

Any phase or sponsor naming "EA-230"

First trial start

2026

Oct 29, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "EA-230", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Coronary Artery Disease (CAD)
  • Coronary Artery Bypass Graft Surgery(CABG)

Approved drugs for the same conditions: Coronary artery disease and heart attack

Largest trials

Live from ClinicalTrials.gov: studies naming "EA-230" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 234,701 on PubMed

Also in development for Coronary Artery Disease (CAD)

  • SRSD107Phase 22 trials

    Sirius Therapeutics Co., Ltd. · Venous Thromboembolism, Coronary Artery Disease (CAD), Peripheral Arterial Disease

  • A195Phase 21 trial

    XyloCor Therapeutics, Inc. · Coronary Artery Disease (CAD)

  • XC001Phase 21 trial

    XyloCor Therapeutics, Inc. · Coronary Artery Disease (CAD)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.